Latest & greatest articles for pneumonia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on pneumonia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on pneumonia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for pneumonia

141. Antibiotics for treating community-acquired pneumonia in people with sickle cell disease. Full Text available with Trip Pro

Antibiotics for treating community-acquired pneumonia in people with sickle cell disease. As a consequence of their condition, people with sickle cell disease are at high risk of developing an acute infection of the pulmonary parenchyma called community-acquired pneumonia. Many different bacteria can cause this infection and antibiotic treatment is generally needed to resolve it. There is no standardized approach to antibiotic therapy and treatment is likely to vary from country to country (...) . Thus, there is a need to identify the efficacy and safety of different antibiotic treatment approaches for people with sickle cell disease suffering from community-acquired pneumonia. This is an update of a previously published Cochrane Review.To determine the efficacy and safety of the antibiotic treatment approaches (monotherapy or combined) for people with sickle cell disease suffering from community-acquired pneumonia.We searched The Group's Haemoglobinopathies Trials Register (01 September

2016 Cochrane

142. A semi-synthetic oligosaccharide conjugate vaccine candidate confers protection against Streptococcus pneumoniae serotype 3 infection Full Text available with Trip Pro

A semi-synthetic oligosaccharide conjugate vaccine candidate confers protection against Streptococcus pneumoniae serotype 3 infection The identification of immunogenic glycotopes that render glycoconjugate vaccines protective is key to improving vaccine efficacy. Synthetic oligosaccharides are an attractive alternative to the heterogeneous preparations of purified polysaccharides that most marketed glycoconjugate vaccines are based on. To investigate the potency of semi-synthetic (...) glycoconjugates, we chose the least-efficient serotype in the current pneumococcal conjugate vaccine Prevnar 13, Streptococcus pneumoniae serotype 3 (ST3). Glycan arrays containing synthetic ST3 repeating unit oligosaccharides were used to screen a human reference serum for antibodies and to define the recognition site of two ST3-specific protective monoclonal antibodies. The glycan array screens identified a tetrasaccharide that was selected for in-depth immunological evaluation. The tetrasaccharide-CRM197

2016 Cell chemical biology

143. Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia Full Text available with Trip Pro

Pathogen- and antibiotic-specific effects of prednisone in community-acquired pneumonia In a double-blind, randomised, placebo-controlled trial of hospitalised patients with community-acquired pneumonia (CAP), we demonstrated shorter time to clinical stability (TTCS) with adjunct corticosteroid therapy compared with placebo.We did a pre-planned, exploratory analysis of any association between microbiological diagnosis, antibiotic treatment and procalcitonin level and effect of prednisone (...) subgroups. We found evidence for a different prednisone response in patients with pneumococcal pneumonia in whom intravenous antibiotic duration was not shorter (interaction p=0.01) with prednisone, as was observed in the remaining study population. In patients without macrolide treatment, rehospitalisations were not lower with prednisone (interaction p=0.04). After adjustment for multiple testing, these subgroup effects were no longer significant.Prednisone was associated with shorter TTCS independent

2016 EvidenceUpdates

144. Ventilator associated events should trump ventilator associated pneumonia Full Text available with Trip Pro

Ventilator associated events should trump ventilator associated pneumonia 28979524 2019 01 16 1751-1437 17 4 2016 Nov Journal of the Intensive Care Society J Intensive Care Soc Ventilator associated events should trump ventilator associated pneumonia. 358 10.1177/1751143716651290 Thomas Matt M Intensive Care Medicine, North Bristol NHS Trust, Bristol, UK. eng Journal Article 2016 10 25 England J Intensive Care Soc 101538668 1751-1437 2017 10 6 6 0 2017 10 6 6 0 2017 10 6 6 1 ppublish 28979524

2016 Journal of the Intensive Care Society

145. Validation of risk scoring models for predicting stroke-associated pneumonia in patients with ischaemic stroke Full Text available with Trip Pro

Validation of risk scoring models for predicting stroke-associated pneumonia in patients with ischaemic stroke Various risk scoring models have been developed to predict stroke-associated pneumonia (SAP). We aim to determine whether these risk models could effectively predict SAP in Chinese patients with ischaemic stroke (IS).Consecutive patients with IS in West China hospital between January 2011 and September 2013 were included to assess the predictive performance of risk scoring models (...) , including Chumbler's score, A2DS2 and AISAPS. The area under the receiver operating characteristic curve (AUROC) was used to evaluate the performance of each risk model in predicting pneumonia.A total of 1569 consecutive patients with IS within 30 days of onset in West China hospital were included. The incidence of pneumonia is 15.3%. The AUROC of Chumbler's score, A2DS2 and AISAPS was 0.659, 0.728 and 0.758, respectively, and AISAPS had the highest AUROC.A2DS2 and AISAPS had acceptable discriminatory

2016 Stroke and vascular neurology

146. Pneumococcal urinary antigen test use in diagnosis and treatment of pneumonia in seven Utah hospitals Full Text available with Trip Pro

Pneumococcal urinary antigen test use in diagnosis and treatment of pneumonia in seven Utah hospitals The pneumocococcal urine antigen test increases specific microbiological diagnosis over conventional culture methods in pneumonia patients. Data are limited regarding its yield and effect on antibiotic prescribing among patients with community-onset pneumonia in clinical practice. We performed a secondary analysis of 2837 emergency department patients admitted to seven Utah hospitals over 2 (...)  years with international diagnostic codes version 9 codes and radiographic evidence of pneumonia. Mean age was 64.2 years, 47.2% were male and all-cause 30-day mortality was 9.6%. Urinary antigen testing was performed in 1110 (39%) patients yielding 134 (12%) positives. Intensive care unit patients were more likely to undergo testing, and have a positive result (15% versus 8.8% for ward patients; p<0.01). Patients with risk factors for healthcare-associated pneumonia had fewer urinary antigen tests

2016 ERJ open research

147. Subglottic secretion drainage for the prevention of ventilator-associated pneumonia: A systematic review and meta-analysis

Subglottic secretion drainage for the prevention of ventilator-associated pneumonia: A systematic review and meta-analysis PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2016 PedsCCM Evidence-Based Journal Club

148. Riociguat (Adempas): not for use in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias

Riociguat (Adempas): not for use in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias Riociguat (Adempas): not for use in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias - GOV.UK GOV.UK uses cookies to make the site simpler. Search Riociguat (Adempas): not for use in patients with pulmonary hypertension associated with idiopathic interstitial pneumonias Patients with pulmonary hypertension associated with idiopathic (...) interstitial pneumonias should not be treated with riociguat in light of interim results from a recently terminated study. Published 8 August 2016 From: Therapeutic area: , Contents Advice for healthcare professionals: patients with pulmonary hypertension associated with idiopathic interstitial pneumonias (PH-IIP) should not be treated with riociguat. PH-IIP is not authorised indication for riociguat riociguat treatment should be discontinued in any patient with PH-IIP. The patient’s clinical status should

2016 MHRA Drug Safety Update

149. Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial Full Text available with Trip Pro

Duration of Antibiotic Treatment in Community-Acquired Pneumonia: A Multicenter Randomized Clinical Trial The optimal duration of antibiotic treatment for community-acquired pneumonia (CAP) has not been well established.To validate Infectious Diseases Society of America/American Thoracic Society guidelines for duration of antibiotic treatment in hospitalized patients with CAP.This study was a multicenter, noninferiority randomized clinical trial performed at 4 teaching hospitals in Spain from

2016 EvidenceUpdates Controlled trial quality: uncertain

150. Predicting 2-Year Risk of Developing Pneumonia in Older Adults without Dementia Full Text available with Trip Pro

Predicting 2-Year Risk of Developing Pneumonia in Older Adults without Dementia To develop three prognostic indices of varying degree of required detail for 2-year pneumonia risk in older adults.Retrospective cohort study.Group Health (GH), an integrated healthcare delivery system.Community-dwelling dementia-free individuals aged 65 and older who had been GH members for at least 2 years before start of follow-up and were enrolled in the Adult Changes in Thought study (N = 3,375; development (...) cohort, n = 2,250; validation cohort, n = 1,125.Potential pneumonia risk factors were identified from questionnaire data and interviewer assessments of functional status, medical history, smoking and alcohol use, cognitive function, personal care, and problem solving. Risk factors were also identified based on physical measures such as grip strength and gait speed and administrative database information on comorbid illnesses, laboratory tests, and prescriptions dispensed. Incident community-acquired

2016 EvidenceUpdates

151. Empiric antimicrobial therapy for ventilator-associated pneumonia after brain injury Full Text available with Trip Pro

Empiric antimicrobial therapy for ventilator-associated pneumonia after brain injury Issues regarding recommendations on empiric antimicrobial therapy for ventilator-associated pneumonia (VAP) have emerged in specific populations.To develop and validate a score to guide empiric therapy in brain-injured patients with VAP, we prospectively followed a cohort of 379 brain-injured patients in five intensive care units. The score was externally validated in an independent cohort of 252 brain-injured

2016 EvidenceUpdates

152. Inpatient rehabilitation improves functional capacity, peripheral muscle strength and quality of life in patients with community-acquired pneumonia: a randomised trial Full Text available with Trip Pro

Inpatient rehabilitation improves functional capacity, peripheral muscle strength and quality of life in patients with community-acquired pneumonia: a randomised trial Among people who are hospitalised for community-acquired pneumonia, does an inpatient exercise-based rehabilitation program improve functional outcomes, symptoms, quality of life and length of hospital stay more than a respiratory physiotherapy regimen?Randomised trial with concealed allocation, intention-to-treat analysis

2016 EvidenceUpdates Controlled trial quality: predicted high

153. Antibiotic preferences for childhood pneumonia vary by physician type and European region Full Text available with Trip Pro

Antibiotic preferences for childhood pneumonia vary by physician type and European region Survey of EAPRASnet and @PREPARE_EUROPE members reveals heterogeneity of antibiotic choice for childhood pneumonia http://ow.ly/4mIS2P.

2016 ERJ open research

154. The Intensive Care Society recommended bundle of interventions for the prevention of ventilator-associated pneumonia Full Text available with Trip Pro

The Intensive Care Society recommended bundle of interventions for the prevention of ventilator-associated pneumonia Ventilator-associated pneumonia is an important healthcare-associated infection. Interventions for the prevention of ventilator-associated pneumonia are often used within bundles of care. Recent evidence has challenged widespread practices mandating a review of subject. This article outlines guidance for ventilator-associated pneumonia prevention.

2016 Journal of the Intensive Care Society

155. Responses to Bacteria, Virus, and Malaria Distinguish the Etiology of Pediatric Clinical Pneumonia Full Text available with Trip Pro

Responses to Bacteria, Virus, and Malaria Distinguish the Etiology of Pediatric Clinical Pneumonia Plasma-detectable biomarkers that rapidly and accurately diagnose bacterial infections in children with suspected pneumonia could reduce the morbidity of respiratory disease and decrease the unnecessary use of antibiotic therapy.Using 56 markers measured in a multiplexed immunoassay, we sought to identify proteins and protein combinations that could discriminate bacterial from viral or malarial (...) diagnoses.We selected 80 patients with clinically diagnosed pneumonia (as defined by the World Health Organization) who also met criteria for bacterial, viral, or malarial infection based on clinical, radiographic, and laboratory results. Ten healthy community control subjects were enrolled to assess marker reliability. Patients were subdivided into two sets: one for identifying potential markers and another for validating them.Three proteins (haptoglobin, tumor necrosis factor receptor 2 or IL-10

2016 EvidenceUpdates

156. CURB-65 Performance among Admitted and Discharged Emergency Department Patients with Community Acquired Pneumonia Full Text available with Trip Pro

CURB-65 Performance among Admitted and Discharged Emergency Department Patients with Community Acquired Pneumonia Pneumonia severity tools were primarily developed in cohorts of hospitalized patients, limiting their applicability to the emergency department (ED). We describe current community ED admission practices and examine the accuracy of the CURB-65 to predict 30-day mortality for patients, either discharged or admitted with community-acquired pneumonia (CAP).A retrospective, observational

2016 EvidenceUpdates

157. Prevalence and Risk Factors associated with Extended Spectrum Beta Lactamase Producing Escherichia coli and Klebsiella pneumoniae Isolates in Hospitalized Patients in Kashan (Iran) Full Text available with Trip Pro

Prevalence and Risk Factors associated with Extended Spectrum Beta Lactamase Producing Escherichia coli and Klebsiella pneumoniae Isolates in Hospitalized Patients in Kashan (Iran) Production of extended spectrum beta lactamase (ESBL) is an important mechanism of antimicrobial resistance in Escherichia coli (E. coli) and Klebsiella pneumoniae (K. pneumoniae) isolates. This study was performed to determine the prevalence and risk factors associated with ESBL producing strains of E. coli and K (...) . pneumoniae.In this cross-sectional study, 250 strains (134 E. coli and 116 K. pneumoniae) were obtained, and ESBL producing isolates were detected by the combination disk test in Shahid Beheshti Hospital in Kashan, Iran, from February 2012 to June 2013. Antimicrobial resistance was screened by the disk diffusion method and was confirmed by E-test. Furthermore, risk factors of ESBL producing E. coli and K. pneumoniae microorganisms were determined. Data were analyzed by SPSS version 16, using descriptive

2016 Electronic physician

158. Intensive Care Unit Admission and Mortality Among Medicare Beneficiaries With Pneumonia--Reply Full Text available with Trip Pro

Intensive Care Unit Admission and Mortality Among Medicare Beneficiaries With Pneumonia--Reply 27002455 2016 03 24 2018 12 02 1538-3598 315 12 2016 Mar 22-29 JAMA JAMA Intensive Care Unit Admission and Mortality Among Medicare Beneficiaries With Pneumonia--Reply. 1285 10.1001/jama.2015.18032 Valley Thomas S TS Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor. Ryan Andrew M AM Center for Health Outcomes and Policy, University of Michigan, Ann Arbor. Cooke Colin (...) R CR Division of Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor. eng K08 HS020672 HS AHRQ HHS United States Letter Comment United States JAMA 7501160 0098-7484 AIM IM JAMA. 2015 Sep 22-29;314(12):1272-9 26393850 JAMA. 2016 Mar 22-29;315(12):1284-5 27002453 Female Hospital Mortality Hospitalization statistics & numerical data Humans Intensive Care Units statistics & numerical data Male Pneumonia mortality 2016 3 23 6 0 2016 3 24 6 0 2016 3 25 6 0 ppublish 27002455 2504804

2016 JAMA

159. Association of Admission to Veterans Affairs Hospitals vs Non-Veterans Affairs Hospitals With Mortality and Readmission Rates Among Older Men Hospitalized With Acute Myocardial Infarction, Heart Failure, or Pneumonia. Full Text available with Trip Pro

Association of Admission to Veterans Affairs Hospitals vs Non-Veterans Affairs Hospitals With Mortality and Readmission Rates Among Older Men Hospitalized With Acute Myocardial Infarction, Heart Failure, or Pneumonia. Little contemporary information is available about comparative performance between Veterans Affairs (VA) and non-VA hospitals, particularly related to mortality and readmission rates, 2 important outcomes of care.To assess and compare mortality and readmission rates among men (...) in VA and non-VA hospitals.Cross-sectional analysis involving male Medicare fee-for-service beneficiaries aged 65 years or older hospitalized between 2010 and 2013 in VA and non-VA acute care hospitals for acute myocardial infarction (AMI), heart failure (HF), or pneumonia using the Medicare Standard Analytic Files and Enrollment Database together with VA administrative claims data. To avoid confounding geographic effects with health care system effects, we studied VA and non-VA hospitals within

2016 JAMA

160. Nebulised colistin for ventilator-associated pneumonia prevention Full Text available with Trip Pro

Nebulised colistin for ventilator-associated pneumonia prevention We evaluated whether prophylactic nebulised colistin could reduce ventilator-associated pneumonia (VAP) rates in an intensive care unit (ICU) setting with prevalent multidrug-resistant (MDR) bacteria.We used a single-centre, two-arm, randomised, open-label, controlled trial in a 12-bed ICU in the University Hospital of Larissa, Greece. Patient inclusion criteria included mechanical ventilation of >48 h. The two arms consisted

2016 EvidenceUpdates Controlled trial quality: predicted high